IDWeek 2024: Prevention and treatment for HIV – clinical trials and policy challenges
Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.
IDWeek 2024: Novel antimicrobials poised to make a difference
Invasive fungal infections are another top concern, as outlined by the World Health Organization’s Fungal Priority Pathogens ...
Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024
ATI-1701 provides full protection against lethal tularemia in animal models after one yearCompany to provide update on tularemia vaccine ...
emjreviews.com3d
Race and Socioeconomic Factors Reveal Low Vaccine Rates: IDWeek 2024
A new study presented at IDWeek 2024 reveals that race and socioeconomic vulnerabilities significantly impact vaccine uptake ...
emjreviews.com4d
Pre-Exposure Prophylaxis Uptake Across US: IDWeek 2024
New IDWeek 2024 study reveals disparities in PrEP uptake across key U.S. populations. While overall PrEP usage has increased, ...
Morningstar7d
Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
PharmiWeb13d
New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...
Mena FN6d
Appili Therapeutics Presents Update On ATI-1701 Biodefense Vaccine Candidate At Idweek™ 2024
IDWeek 2024TM is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the ...